$ATRX Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ATRIX LABORATORIES INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in ATRIX LABORATORIES INC. Get notifications about new insider transactions in ATRIX LABORATORIES INC for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Nov 23 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | Chief Executive Off ... | Option Exercise | D | 9.50 | 50,000 | 475,000 | 0 | |
Nov 23 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | Chief Executive Off ... | Option Exercise | D | 9.75 | 60,000 | 585,000 | 0 | |
Nov 23 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | Chief Executive Off ... | Sell | D | 0.00 | 146,477 | 0 | 0 | 146.5 K to 0 (-100.00 %) |
Nov 23 2004 | ATRX | ATRIX LABORATORIES ... | DUNCAN MICHAEL R | VP & General Manage ... | Option Exercise | D | 31.00 | 30,000 | 930,000 | 0 | |
Nov 23 2004 | ATRX | ATRIX LABORATORIES ... | DUNCAN MICHAEL R | VP & General Manage ... | Option Exercise | D | 22.32 | 12,000 | 267,840 | 0 | |
Nov 23 2004 | ATRX | ATRIX LABORATORIES ... | DUNCAN MICHAEL R | VP & General Manage ... | Option Exercise | D | 16.46 | 11,000 | 181,060 | 0 | |
Nov 23 2004 | ATRX | ATRIX LABORATORIES ... | DUNCAN MICHAEL R | VP & General Manage ... | Option Exercise | D | 22.83 | 4,000 | 91,320 | 0 | |
Nov 23 2004 | ATRX | ATRIX LABORATORIES ... | DUNCAN MICHAEL R | VP & General Manage ... | Option Exercise | D | 18.13 | 5,000 | 90,625 | 0 | |
Nov 23 2004 | ATRX | ATRIX LABORATORIES ... | DUNCAN MICHAEL R | VP & General Manage ... | Option Exercise | D | 15.56 | 10,000 | 155,630 | 0 | |
Nov 23 2004 | ATRX | ATRIX LABORATORIES ... | DUNCAN MICHAEL R | VP & General Manage ... | Option Exercise | D | 9.50 | 10,000 | 95,000 | 0 | |
Nov 23 2004 | ATRX | ATRIX LABORATORIES ... | DUNCAN MICHAEL R | VP & General Manage ... | Option Exercise | D | 9.75 | 14,200 | 138,450 | 0 | |
Nov 23 2004 | ATRX | ATRIX LABORATORIES ... | DUNCAN MICHAEL R | VP & General Manage ... | Option Exercise | D | 16.50 | 10,000 | 165,000 | 0 | |
Nov 23 2004 | ATRX | ATRIX LABORATORIES ... | DUNCAN MICHAEL R | VP & General Manage ... | Sell | D | 0.00 | 715 | 0 | 0 | 715 to 0 (-100.00 %) |
Nov 23 2004 | ATRX | ATRIX LABORATORIES ... | GOULD GREGORY A | Chief Financial Off ... | Option Exercise | D | 31.00 | 30,000 | 930,000 | 0 | |
Nov 23 2004 | ATRX | ATRIX LABORATORIES ... | GOULD GREGORY A | Chief Financial Off ... | Option Exercise | D | 24.96 | 45,000 | 1,123,200 | 0 | |
Nov 23 2004 | ATRX | ATRIX LABORATORIES ... | GOULD GREGORY A | Chief Financial Off ... | Sell | D | 0.00 | 127 | 0 | 0 | 127 to 0 (-100.00 %) |
Nov 23 2004 | ATRX | ATRIX LABORATORIES ... | GOULD GREGORY A | Chief Financial Off ... | Option Exercise | D | 31.00 | 30,000 | 930,000 | 0 | |
Nov 23 2004 | ATRX | ATRIX LABORATORIES ... | GOULD GREGORY A | Chief Financial Off ... | Option Exercise | D | 24.96 | 45,000 | 1,123,200 | 0 | |
Nov 23 2004 | ATRX | ATRIX LABORATORIES ... | GOULD GREGORY A | Chief Financial Off ... | Sell | D | 0.00 | 127 | 0 | 0 | 127 to 0 (-100.00 %) |
Nov 23 2004 | ATRX | ATRIX LABORATORIES ... | WARREN STEPHEN L | VP Research & Devel ... | Option Exercise | D | 31.00 | 25,000 | 775,000 | 0 | |
Nov 23 2004 | ATRX | ATRIX LABORATORIES ... | WARREN STEPHEN L | VP Research & Devel ... | Option Exercise | D | 22.32 | 15,000 | 334,800 | 0 | |
Nov 23 2004 | ATRX | ATRIX LABORATORIES ... | WARREN STEPHEN L | VP Research & Devel ... | Option Exercise | D | 16.46 | 20,000 | 329,200 | 0 | |
Nov 23 2004 | ATRX | ATRIX LABORATORIES ... | WARREN STEPHEN L | VP Research & Devel ... | Option Exercise | D | 13.41 | 10,000 | 134,100 | 0 | |
Nov 23 2004 | ATRX | ATRIX LABORATORIES ... | WARREN STEPHEN L | VP Research & Devel ... | Option Exercise | D | 21.08 | 50,000 | 1,054,000 | 0 | |
Nov 23 2004 | ATRX | ATRIX LABORATORIES ... | Speights David R | Controller | Option Exercise | D | 30.87 | 10,000 | 308,700 | 0 | |
Nov 23 2004 | ATRX | ATRIX LABORATORIES ... | Speights David R | Controller | Option Exercise | D | 30.87 | 15,000 | 463,050 | 0 | |
Nov 16 2004 | ATRX | ATRIX LABORATORIES ... | DUNCAN MICHAEL R | VP and General Mana ... | Option Exercise | M | 9.75 | 5,000 | 48,750 | 14,200 | |
Nov 16 2004 | ATRX | ATRIX LABORATORIES ... | DUNCAN MICHAEL R | VP and General Mana ... | Sell | S | 30.78 | 5,000 | 153,900 | 715 | 5.7 K to 715 (-87.49 %) |
Nov 16 2004 | ATRX | ATRIX LABORATORIES ... | DUNCAN MICHAEL R | VP and General Mana ... | Buy | M | 9.75 | 5,000 | 48,750 | 5,715 | 715 to 5.7 K (+699.30 %) |
Nov 23 2004 | ATRX | ATRIX LABORATORIES ... | VIETOR RICHARD R | Director | Option Exercise | D | 31.34 | 15,000 | 470,100 | 0 | |
Nov 23 2004 | ATRX | ATRIX LABORATORIES ... | VIETOR RICHARD R | Director | Option Exercise | D | 22.74 | 25,000 | 568,500 | 0 | |
Nov 23 2004 | ATRX | ATRIX LABORATORIES ... | VIETOR RICHARD R | Director | Sell | D | 0.00 | 448 | 0 | 0 | 448 to 0 (-100.00 %) |
Nov 12 2004 | ATRX | ATRIX LABORATORIES ... | GARRETT J STEVEN | Senior VP Clinical ... | Option Exercise | M | 10.06 | 4,500 | 45,281 | 5,500 | |
Nov 12 2004 | ATRX | ATRIX LABORATORIES ... | GARRETT J STEVEN | Senior VP Clinical ... | Sell | S | 30.58 | 4,500 | 137,610 | 3,668 | 8.2 K to 3.7 K (-55.09 %) |
Nov 12 2004 | ATRX | ATRIX LABORATORIES ... | GARRETT J STEVEN | Senior VP Clinical ... | Buy | M | 10.06 | 4,500 | 45,281 | 8,168 | 3.7 K to 8.2 K (+122.68 %) |
Nov 08 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | CEO/Chairman | Option Exercise | M | 9.75 | 10,000 | 97,500 | 60,000 | |
Nov 08 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | CEO/Chairman | Sell | S | 31.01 | 10,000 | 310,100 | 146,477 | 156.5 K to 146.5 K (-6.39 %) |
Nov 08 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | CEO/Chairman | Buy | M | 9.75 | 10,000 | 97,500 | 156,477 | 146.5 K to 156.5 K (+6.83 %) |
Oct 12 2004 | ATRX | ATRIX LABORATORIES ... | GARRETT J STEVEN | Senior VP Clinical ... | Option Exercise | M | 15.56 | 1,200 | 18,676 | 6,800 | |
Oct 12 2004 | ATRX | ATRIX LABORATORIES ... | GARRETT J STEVEN | Senior VP Clinical ... | Option Exercise | M | 12.88 | 3,800 | 48,925 | 0 | |
Oct 12 2004 | ATRX | ATRIX LABORATORIES ... | GARRETT J STEVEN | Senior VP Clinical ... | Sell | S | 30.39 | 1,200 | 36,468 | 3,668 | 4.9 K to 3.7 K (-24.65 %) |
Oct 12 2004 | ATRX | ATRIX LABORATORIES ... | GARRETT J STEVEN | Senior VP Clinical ... | Sell | S | 30.39 | 3,800 | 115,482 | 4,868 | 8.7 K to 4.9 K (-43.84 %) |
Oct 12 2004 | ATRX | ATRIX LABORATORIES ... | GARRETT J STEVEN | Senior VP Clinical ... | Buy | M | 15.56 | 1,200 | 18,676 | 8,668 | 7.5 K to 8.7 K (+16.07 %) |
Oct 12 2004 | ATRX | ATRIX LABORATORIES ... | GARRETT J STEVEN | Senior VP Clinical ... | Buy | M | 12.88 | 3,800 | 48,925 | 7,468 | 3.7 K to 7.5 K (+103.60 %) |
Oct 19 2004 | ATRX | ATRIX LABORATORIES ... | DUNCAN MICHAEL R | VP and General Mana ... | Option Exercise | M | 9.75 | 800 | 7,800 | 19,200 | |
Oct 19 2004 | ATRX | ATRIX LABORATORIES ... | DUNCAN MICHAEL R | VP and General Mana ... | Option Exercise | M | 10.13 | 4,200 | 42,525 | 0 | |
Oct 19 2004 | ATRX | ATRIX LABORATORIES ... | DUNCAN MICHAEL R | VP and General Mana ... | Sell | S | 30.14 | 800 | 24,108 | 715 | 1.5 K to 715 (-52.81 %) |
Oct 19 2004 | ATRX | ATRIX LABORATORIES ... | DUNCAN MICHAEL R | VP and General Mana ... | Buy | M | 9.75 | 800 | 7,800 | 1,515 | 715 to 1.5 K (+111.89 %) |
Oct 19 2004 | ATRX | ATRIX LABORATORIES ... | DUNCAN MICHAEL R | VP and General Mana ... | Sell | S | 30.14 | 4,200 | 126,567 | 715 | 4.9 K to 715 (-85.45 %) |
Oct 19 2004 | ATRX | ATRIX LABORATORIES ... | DUNCAN MICHAEL R | VP and General Mana ... | Buy | M | 10.13 | 4,200 | 42,525 | 4,915 | 715 to 4.9 K (+587.41 %) |
Oct 06 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | CEO/Chairman | Option Exercise | M | 9.75 | 10,000 | 97,500 | 70,000 | |
Oct 06 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | CEO/Chairman | Sell | S | 32.02 | 10,000 | 320,190 | 146,477 | 156.5 K to 146.5 K (-6.39 %) |
Oct 06 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | CEO/Chairman | Buy | M | 9.75 | 10,000 | 97,500 | 156,477 | 146.5 K to 156.5 K (+6.83 %) |
Sep 16 2004 | ATRX | ATRIX LABORATORIES ... | DUNCAN MICHAEL R | VP and General Mana ... | Option Exercise | M | 10.13 | 3,300 | 33,413 | 4,200 | |
Sep 16 2004 | ATRX | ATRIX LABORATORIES ... | DUNCAN MICHAEL R | VP and General Mana ... | Option Exercise | M | 9.63 | 1,700 | 16,363 | 0 | |
Sep 16 2004 | ATRX | ATRIX LABORATORIES ... | DUNCAN MICHAEL R | VP and General Mana ... | Sell | S | 30.12 | 3,300 | 99,396 | 550 | 3.9 K to 550 (-85.71 %) |
Sep 16 2004 | ATRX | ATRIX LABORATORIES ... | DUNCAN MICHAEL R | VP and General Mana ... | Buy | M | 10.13 | 3,300 | 33,413 | 3,850 | 550 to 3.9 K (+600.00 %) |
Sep 16 2004 | ATRX | ATRIX LABORATORIES ... | DUNCAN MICHAEL R | VP and General Mana ... | Sell | S | 30.12 | 1,700 | 51,204 | 550 | 2.3 K to 550 (-75.56 %) |
Sep 16 2004 | ATRX | ATRIX LABORATORIES ... | DUNCAN MICHAEL R | VP and General Mana ... | Buy | M | 9.63 | 1,700 | 16,363 | 2,250 | 550 to 2.3 K (+309.09 %) |
Sep 14 2004 | ATRX | ATRIX LABORATORIES ... | GARRETT J STEVEN | Senior VP Clinical ... | Option Exercise | M | 12.88 | 5,000 | 64,375 | 3,800 | |
Sep 14 2004 | ATRX | ATRIX LABORATORIES ... | GARRETT J STEVEN | Senior VP Clinical ... | Sell | S | 30.00 | 5,000 | 150,000 | 3,500 | 8.5 K to 3.5 K (-58.82 %) |
Sep 14 2004 | ATRX | ATRIX LABORATORIES ... | GARRETT J STEVEN | Senior VP Clinical ... | Buy | M | 12.88 | 5,000 | 64,375 | 8,500 | 3.5 K to 8.5 K (+142.86 %) |
Sep 08 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | CEO/Chairman | Option Exercise | M | 9.75 | 10,000 | 97,500 | 80,000 | |
Sep 08 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | CEO/Chairman | Sell | S | 29.21 | 10,000 | 292,100 | 146,477 | 156.5 K to 146.5 K (-6.39 %) |
Sep 08 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | CEO/Chairman | Buy | M | 9.75 | 10,000 | 97,500 | 156,477 | 146.5 K to 156.5 K (+6.83 %) |
Aug 17 2004 | ATRX | ATRIX LABORATORIES ... | VIETOR RICHARD R | Director | Grant | A | 29.91 | 112 | 3,350 | 448 | 336 to 448 (+33.33 %) |
Aug 17 2004 | ATRX | ATRIX LABORATORIES ... | CAMPBELL H STUART | Director | Grant | A | 29.91 | 145 | 4,337 | 36,059 | 35.9 K to 36.1 K (+0.40 %) |
Aug 16 2004 | ATRX | ATRIX LABORATORIES ... | DUNCAN MICHAEL R | VP and General Mana ... | Option Exercise | M | 9.63 | 1,000 | 9,625 | 1,700 | |
Aug 16 2004 | ATRX | ATRIX LABORATORIES ... | DUNCAN MICHAEL R | VP and General Mana ... | Option Exercise | M | 9.72 | 4,000 | 38,876 | 0 | |
Aug 16 2004 | ATRX | ATRIX LABORATORIES ... | DUNCAN MICHAEL R | VP and General Mana ... | Sell | S | 30.11 | 1,000 | 30,110 | 550 | 1.6 K to 550 (-64.52 %) |
Aug 16 2004 | ATRX | ATRIX LABORATORIES ... | DUNCAN MICHAEL R | VP and General Mana ... | Buy | M | 9.63 | 1,000 | 9,625 | 1,550 | 550 to 1.6 K (+181.82 %) |
Aug 16 2004 | ATRX | ATRIX LABORATORIES ... | DUNCAN MICHAEL R | VP and General Mana ... | Sell | S | 30.11 | 4,000 | 120,440 | 550 | 4.6 K to 550 (-87.91 %) |
Aug 16 2004 | ATRX | ATRIX LABORATORIES ... | DUNCAN MICHAEL R | VP and General Mana ... | Buy | M | 9.72 | 4,000 | 38,876 | 4,550 | 550 to 4.6 K (+727.27 %) |
Aug 11 2004 | ATRX | ATRIX LABORATORIES ... | GARRETT J STEVEN | Senior VP Clinical ... | Option Exercise | M | 9.50 | 5,000 | 47,500 | 0 | |
Aug 11 2004 | ATRX | ATRIX LABORATORIES ... | GARRETT J STEVEN | Senior VP Clinical ... | Sell | S | 30.53 | 5,000 | 152,650 | 3,500 | 8.5 K to 3.5 K (-58.82 %) |
Aug 11 2004 | ATRX | ATRIX LABORATORIES ... | GARRETT J STEVEN | Senior VP Clinical ... | Buy | M | 9.50 | 5,000 | 47,500 | 8,500 | 3.5 K to 8.5 K (+142.86 %) |
Aug 10 2004 | ATRX | ATRIX LABORATORIES ... | GARRETT J STEVEN | Sr VP Clinical Rese ... | Gift | G | 30.25 | 650 | 19,663 | 3,500 | 4.2 K to 3.5 K (-15.66 %) |
Aug 06 2004 | ATRX | ATRIX LABORATORIES ... | COHEN D WALTER | Director | Option Exercise | M | 9.00 | 4,000 | 36,000 | 0 | |
Aug 06 2004 | ATRX | ATRIX LABORATORIES ... | COHEN D WALTER | Director | Option Exercise | M | 9.94 | 4,000 | 39,752 | 0 | |
Aug 06 2004 | ATRX | ATRIX LABORATORIES ... | COHEN D WALTER | Director | Buy | M | 9.00 | 4,000 | 36,000 | 23,583 | 19.6 K to 23.6 K (+20.43 %) |
Aug 06 2004 | ATRX | ATRIX LABORATORIES ... | COHEN D WALTER | Director | Buy | M | 9.94 | 4,000 | 39,752 | 19,583 | 15.6 K to 19.6 K (+25.67 %) |
Aug 05 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | CEO/Chairman | Option Exercise | M | 9.75 | 10,000 | 97,500 | 90,000 | |
Aug 05 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | CEO/Chairman | Sell | S | 30.57 | 10,000 | 305,700 | 146,477 | 156.5 K to 146.5 K (-6.39 %) |
Aug 05 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | CEO/Chairman | Buy | M | 9.75 | 10,000 | 97,500 | 156,477 | 146.5 K to 156.5 K (+6.83 %) |
Jul 27 2004 | ATRX | ATRIX LABORATORIES ... | GARRETT J STEVEN | Sr VP Clinical Rese ... | Gift | G | 34.13 | 2,950 | 100,684 | 4,150 | 7.1 K to 4.2 K (-41.55 %) |
Jul 19 2004 | ATRX | ATRIX LABORATORIES ... | WARREN STEPHEN L | VP R&D and CSO | Option Exercise | M | 13.41 | 5,000 | 67,050 | 10,000 | |
Jul 19 2004 | ATRX | ATRIX LABORATORIES ... | WARREN STEPHEN L | VP R&D and CSO | Sell | S | 33.50 | 5,000 | 167,500 | 0 | 5 K to 0 (-100.00 %) |
Jul 19 2004 | ATRX | ATRIX LABORATORIES ... | WARREN STEPHEN L | VP R&D and CSO | Buy | M | 13.41 | 5,000 | 67,050 | 5,000 | 0 to 5 K |
Jul 19 2004 | ATRX | ATRIX LABORATORIES ... | DUNCAN MICHAEL R | VP and General Mana ... | Option Exercise | M | 9.72 | 7,000 | 68,033 | 4,000 | |
Jul 19 2004 | ATRX | ATRIX LABORATORIES ... | DUNCAN MICHAEL R | VP and General Mana ... | Sell | S | 33.50 | 7,000 | 234,500 | 550 | 7.6 K to 550 (-92.72 %) |
Jul 19 2004 | ATRX | ATRIX LABORATORIES ... | DUNCAN MICHAEL R | VP and General Mana ... | Buy | M | 9.72 | 7,000 | 68,033 | 7,550 | 550 to 7.6 K (+1,272.73 %) |
Jul 12 2004 | ATRX | ATRIX LABORATORIES ... | GARRETT J STEVEN | Senior VP Clinical ... | Option Exercise | M | 9.50 | 5,000 | 47,500 | 5,000 | |
Jul 12 2004 | ATRX | ATRIX LABORATORIES ... | GARRETT J STEVEN | Senior VP Clinical ... | Sell | S | 31.96 | 5,000 | 159,775 | 7,100 | 12.1 K to 7.1 K (-41.32 %) |
Jul 12 2004 | ATRX | ATRIX LABORATORIES ... | GARRETT J STEVEN | Senior VP Clinical ... | Buy | M | 9.50 | 5,000 | 47,500 | 12,100 | 7.1 K to 12.1 K (+70.42 %) |
Jul 06 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | CEO/Chairman | Option Exercise | M | 9.72 | 10,000 | 97,190 | 0 | |
Jul 06 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | CEO/Chairman | Sell | S | 33.04 | 10,000 | 330,400 | 146,477 | 156.5 K to 146.5 K (-6.39 %) |
Jul 06 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | CEO/Chairman | Buy | M | 9.72 | 10,000 | 97,190 | 156,477 | 146.5 K to 156.5 K (+6.83 %) |
Jun 29 2004 | ATRX | ATRIX LABORATORIES ... | Speights David R | Corporate Controlle ... | Option Exercise | A | 32.85 | 10,000 | 328,500 | 10,000 | |
Jun 16 2004 | ATRX | ATRIX LABORATORIES ... | GARRETT J STEVEN | Senior VP Clinical ... | Option Exercise | M | 12.88 | 1,200 | 15,450 | 8,800 | |
Jun 16 2004 | ATRX | ATRIX LABORATORIES ... | GARRETT J STEVEN | Senior VP Clinical ... | Sell | S | 32.77 | 1,200 | 39,324 | 7,100 | 8.3 K to 7.1 K (-14.46 %) |
Jun 16 2004 | ATRX | ATRIX LABORATORIES ... | GARRETT J STEVEN | Senior VP Clinical ... | Buy | M | 12.88 | 1,200 | 15,450 | 8,300 | 7.1 K to 8.3 K (+16.90 %) |
Jun 16 2004 | ATRX | ATRIX LABORATORIES ... | GARRETT J STEVEN | Senior VP Clinical ... | Sell | S | 32.77 | 3,800 | 124,526 | 7,100 | 10.9 K to 7.1 K (-34.86 %) |
Jun 08 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | CEO/Chairman | Option Exercise | M | 9.72 | 4,000 | 38,876 | 10,000 | |
Jun 08 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | CEO/Chairman | Option Exercise | M | 9.94 | 4,000 | 39,752 | 0 | |
Jun 08 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | CEO/Chairman | Option Exercise | M | 9.63 | 2,000 | 19,250 | 0 | |
Jun 08 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | CEO/Chairman | Sell | S | 28.50 | 10,000 | 284,950 | 146,477 | 156.5 K to 146.5 K (-6.39 %) |
Jun 08 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | CEO/Chairman | Buy | M | 9.72 | 4,000 | 38,876 | 156,477 | 152.5 K to 156.5 K (+2.62 %) |
Jun 08 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | CEO/Chairman | Buy | M | 9.94 | 4,000 | 39,752 | 152,477 | 148.5 K to 152.5 K (+2.69 %) |
Jun 08 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | CEO/Chairman | Buy | M | 9.63 | 2,000 | 19,250 | 148,477 | 146.5 K to 148.5 K (+1.37 %) |
Jun 08 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | CEO/Chairman | Option Exercise | M | 9.72 | 4,000 | 38,876 | 10,000 | |
Jun 08 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | CEO/Chairman | Option Exercise | M | 9.94 | 4,000 | 39,752 | 0 | |
Jun 08 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | CEO/Chairman | Option Exercise | M | 9.63 | 2,000 | 19,250 | 0 | |
Jun 08 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | CEO/Chairman | Sell | S | 28.50 | 10,000 | 284,950 | 146,477 | 156.5 K to 146.5 K (-6.39 %) |
Jun 08 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | CEO/Chairman | Buy | M | 9.72 | 4,000 | 38,876 | 156,477 | 152.5 K to 156.5 K (+2.62 %) |
Jun 08 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | CEO/Chairman | Buy | M | 9.94 | 4,000 | 39,752 | 152,477 | 148.5 K to 152.5 K (+2.69 %) |
Jun 08 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | CEO/Chairman | Buy | M | 9.63 | 2,000 | 19,250 | 148,477 | 146.5 K to 148.5 K (+1.37 %) |
May 17 2004 | ATRX | ATRIX LABORATORIES ... | GARRETT J STEVEN | Senior VP Clinical ... | Sell | S | 27.02 | 2,000 | 54,030 | 10,900 | 12.9 K to 10.9 K (-15.50 %) |
May 10 2004 | ATRX | ATRIX LABORATORIES ... | GARRETT J STEVEN | Sr VP Clinical Rese ... | Option Exercise | A | 31.00 | 20,000 | 620,000 | 20,000 | |
May 10 2004 | ATRX | ATRIX LABORATORIES ... | WARREN STEPHEN L | VP R&D and CSO | Option Exercise | A | 31.00 | 25,000 | 775,000 | 25,000 | |
May 10 2004 | ATRX | ATRIX LABORATORIES ... | WARREN STEPHEN L | VP R&D and CSO | Option Exercise | A | 31.00 | 25,000 | 775,000 | 25,000 | |
May 10 2004 | ATRX | ATRIX LABORATORIES ... | DUNCAN MICHAEL R | VP and General Mana ... | Option Exercise | A | 31.00 | 30,000 | 930,000 | 30,000 | |
May 10 2004 | ATRX | ATRIX LABORATORIES ... | GOULD GREGORY A | Chief Financial Off ... | Option Exercise | A | 31.00 | 30,000 | 930,000 | 30,000 | |
May 10 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | Chief Executive Off ... | Option Exercise | A | 31.00 | 50,000 | 1,550,000 | 50,000 | |
May 10 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | Chief Executive Off ... | Option Exercise | M | 9.63 | 8,000 | 77,000 | 2,000 | |
May 10 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | Chief Executive Off ... | Option Exercise | M | 6.88 | 2,000 | 13,760 | 0 | |
May 10 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | Chief Executive Off ... | Sell | S | 31.16 | 10,000 | 311,620 | 146,477 | 156.5 K to 146.5 K (-6.39 %) |
May 10 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | Chief Executive Off ... | Buy | M | 9.63 | 8,000 | 77,000 | 156,477 | 148.5 K to 156.5 K (+5.39 %) |
May 10 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | Chief Executive Off ... | Buy | M | 6.88 | 2,000 | 13,760 | 148,477 | 146.5 K to 148.5 K (+1.37 %) |
May 10 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | Chief Executive Off ... | Option Exercise | A | 31.00 | 50,000 | 1,550,000 | 50,000 | |
May 10 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | Chief Executive Off ... | Option Exercise | M | 9.63 | 8,000 | 77,000 | 2,000 | |
May 10 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | Chief Executive Off ... | Option Exercise | M | 6.88 | 2,000 | 13,760 | 0 | |
May 10 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | Chief Executive Off ... | Sell | S | 31.16 | 10,000 | 311,620 | 146,477 | 156.5 K to 146.5 K (-6.39 %) |
May 10 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | Chief Executive Off ... | Buy | M | 9.63 | 8,000 | 77,000 | 156,477 | 148.5 K to 156.5 K (+5.39 %) |
May 10 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | Chief Executive Off ... | Buy | M | 6.88 | 2,000 | 13,760 | 148,477 | 146.5 K to 148.5 K (+1.37 %) |
May 05 2004 | ATRX | ATRIX LABORATORIES ... | VIETOR RICHARD R | Director | Option Exercise | A | 31.34 | 15,000 | 470,100 | 15,000 | |
May 05 2004 | ATRX | ATRIX LABORATORIES ... | O CONNOR C RODNEY | Director | Option Exercise | A | 31.34 | 15,000 | 470,100 | 15,000 | |
May 05 2004 | ATRX | ATRIX LABORATORIES ... | VUTURO GEORGE J | Director | Option Exercise | A | 31.34 | 15,000 | 470,100 | 15,000 | |
May 05 2004 | ATRX | ATRIX LABORATORIES ... | VUTURO GEORGE J | Director | Grant | A | 31.34 | 477 | 14,949 | 26,336 | 25.9 K to 26.3 K (+1.84 %) |
May 05 2004 | ATRX | ATRIX LABORATORIES ... | VUTURO GEORGE J | Director | Option Exercise | A | 31.34 | 15,000 | 470,100 | 15,000 | |
May 05 2004 | ATRX | ATRIX LABORATORIES ... | VUTURO GEORGE J | Director | Grant | A | 31.34 | 477 | 14,949 | 26,336 | 25.9 K to 26.3 K (+1.84 %) |
May 05 2004 | ATRX | ATRIX LABORATORIES ... | BAZAN NICHOLAS G | Director | Option Exercise | A | 31.34 | 33,000 | 1,034,220 | 33,000 | |
May 05 2004 | ATRX | ATRIX LABORATORIES ... | BAZAN NICHOLAS G | Director | Grant | A | 31.34 | 477 | 14,949 | 3,517 | 3 K to 3.5 K (+15.69 %) |
May 05 2004 | ATRX | ATRIX LABORATORIES ... | CAMPBELL H STUART | Director | Option Exercise | A | 31.34 | 15,000 | 470,100 | 15,000 | |
May 05 2004 | ATRX | ATRIX LABORATORIES ... | CAMPBELL H STUART | Director | Grant | A | 31.34 | 521 | 16,328 | 35,914 | 35.4 K to 35.9 K (+1.47 %) |
May 05 2004 | ATRX | ATRIX LABORATORIES ... | COHEN D WALTER | Director | Option Exercise | A | 31.34 | 15,000 | 470,100 | 15,000 | |
May 05 2004 | ATRX | ATRIX LABORATORIES ... | COHEN D WALTER | Director | Option Exercise | A | 31.34 | 15,000 | 470,100 | 15,000 | |
Apr 19 2004 | ATRX | ATRIX LABORATORIES ... | GARRETT J STEVEN | Sr VP Clincal Resea ... | Option Exercise | M | 15.56 | 2,000 | 31,126 | 8,000 | |
Apr 19 2004 | ATRX | ATRIX LABORATORIES ... | GARRETT J STEVEN | Sr VP Clincal Resea ... | Sell | S | 29.26 | 2,000 | 58,520 | 12,900 | 14.9 K to 12.9 K (-13.42 %) |
Apr 19 2004 | ATRX | ATRIX LABORATORIES ... | GARRETT J STEVEN | Sr VP Clincal Resea ... | Buy | M | 15.56 | 2,000 | 31,126 | 14,900 | 12.9 K to 14.9 K (+15.50 %) |
Apr 06 2004 | ATRX | ATRIX LABORATORIES ... | BETHUNE DAVID R | Chairman and CEO | Option Exercise | M | 6.88 | 10,000 | 68,800 | 2,000 |